Emerald Advisers’s Tvardi Therapeutics TVRD Stock Holding History

Emerald Advisers’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-2,592	Closed	-$1.74M	–	444
2014 Q1	$1.74M	Buy	+2,592	New	+$1.53M	0.1%	210

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Emerald Advisers's TVRD Position: Q2 2014 in Review

Emerald Advisers sold out of Tvardi Therapeutics (TVRD) in Q2 2014, closing a stake of 2,592 shares — an estimated $1.74M sold.

Emerald Advisers first reported a position in TVRD in Q1 2014 and held it in 1 quarter. The position peaked at $1.74M in Q1 2014. 49 funds tracked by Wall St. Rank hold TVRD as of Q2 2014.

Emerald Advisers reported no remaining Tvardi Therapeutics position as of Q2 2014 after selling out during the quarter.
Emerald Advisers sold 2,592 Tvardi Therapeutics shares in Q2 2014, an estimated $1.74M.
Emerald Advisers first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 1 quarter.
Emerald Advisers's Tvardi Therapeutics position peaked at $1.74M in Q1 2014.
49 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2014.

Based on Emerald Advisers's 13F filing for Q2 2014, filed 17 Jul 2014.